APA (7th ed.) Citation

Patel, R., Singh, A., Meng, Z., Baldridge, A. S., Addison, D., & Akhter, N. (2024). The risk vs. benefit calculus of anticoagulation in patients with ibrutinib-related atrial fibrillation. Leukemia & Lymphoma, 65(2), 168. https://doi.org/10.1080/10428194.2023.2278433

Chicago Style (17th ed.) Citation

Patel, Ruchi, Arushi Singh, Zhiying Meng, Abigail S. Baldridge, Daniel Addison, and Nausheen Akhter. "The Risk Vs. Benefit Calculus of Anticoagulation in Patients with Ibrutinib-related Atrial Fibrillation." Leukemia & Lymphoma 65, no. 2 (2024): 168. https://doi.org/10.1080/10428194.2023.2278433.

MLA (9th ed.) Citation

Patel, Ruchi, et al. "The Risk Vs. Benefit Calculus of Anticoagulation in Patients with Ibrutinib-related Atrial Fibrillation." Leukemia & Lymphoma, vol. 65, no. 2, 2024, p. 168, https://doi.org/10.1080/10428194.2023.2278433.